Johnson & Johnson : TREMFYA® (guselkumab) Provides Sustained Improvements Across All Minimal Disease Activity Domains for Adults Living with Active Psoriatic Arthritis in Phase 3b Trial

SPRING HOUSE, PENNSYLVANIA, May 31, 2023 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 3b COSMOS clinical trial showing that treatment... | May 31, 2023

Related Keywords

Horsham , Saskatchewan , Canada , Pennsylvania , United States , Milan , Lombardia , Italy , Japan , Spring House , Canadian , Zismand Comorbidities , Laura Coates , Terence Rooney , Craig Stoltz , Scandj Rheumatol , National Library Of Medicine , Stanford Health Assessment Questionnaire , Canadian Agency For Drugs Technologies In Health , Janssen Scientific Affairs , Janssen Pharmaceutical Companies , Arthritis Foundation , Devices Agency , Exchange Commission , Johnson , Janssen Pharmaceutical Companies Of Johnson , Japan Pharmaceuticals , European Medicines Agency , Companies Of Johnson , None Of The Janssen Pharmaceutical Companies , Drug Administration , Janssen Biotech Inc , Health Assessment Questionnaire , Janssen Research Development , University Of Oxford , Senior Clinical Research , National Psoriasis Foundation , European Congress , Psoriasis Area , Severity Index , Leeds Enthesitis Index , Senior Clinical Research Fellow , Vice President , Maternal Fetal Immunology Disease Area Leader , Janssen Research , Psoriatic Arthritis , Allergic Reactions Stop , Prescribing Information , Medication Guidefor , Pharmaceutical Companies , Infectious Diseases , Janssen Biotech , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Inadequate Response , Receiving Guselkumab , Between Patient , Physician Global Assessment Over Time , Accessed May , Rheum Dis , Swollen Joint Counts , Modified Rodnan Skin Score , Early Diffuse Cutaneous Systemic Sclerosis , Prospective Registry , Early Systemic Sclerosis , National Library , Accessed April , Active Psoriatic Arthritis , Anti Tumor Necrosis Factor Alpha , New Phase , Data Show First In Class , Achieved Robust Joint Symptom Improvement , Complete Skin Clearance , Tumor Necrosis Factor Inhibition , Ann Rheum Dis , Provides Sustained Improvement , Patients Who Were Biologic Na , Guselkumab Through , Patients With Active Psoriatic Arthritis , Previously Received , Inhibitor Treatment , Placebo Controlled Phase , Term Efficacy , Monoclonal Antibody Specific , Through Two Years , Results From , Placebo Controlled Study Conducted , Biologic Naive Patients With Active Psoriatic , Arthritis Rheumatol , Study Evaluating , Guselkumab Administered Subcutaneously , Alpha Agent , Participants With Active Psoriatic , Sausage Finger Swelling You Should Know , About Psoriatic , Immune Based Ther Vaccines , Last Updated July , Medical Devices , Tremfya Report , Canadian Agency , Inflammatory Mononuclear Phagocyte , T Cell Profiles , Psoriatic Skin , Specific Monoclonal Antibody , Myeloid Cells , Potently Neutralises , Johnson Stock Exchange , News , Information , Press Release , Spring , Bay , 023 , The , Janssen , Harmaceutical , Companies , F , Oday , Nnounced , Few , Data , Rom , Hase , Tb , Cosmos , Linical , Trial , Showing , Hat Jnj Us4781601046 ,